Skip to main content

Table 3 Cox regression of baseline values in uni- and multivariate (*) analysis

From: Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up

Baseline values

Whole cohort

PAH

PAH with comorbidities

Cox regression

n

Cox regression

n

Cox regression

n

p-value

p-value

p-value

Survival

 6MWD

< 0.0001

137

0.006

65

0.052

42

 NT-proBNP

0.006

102

0.011

63

0.356

37

 WHO-FC

0.005*

121

0.001*

74

0.403

46

 RA area

0.254

133

0.991

82

0.472

49

 RV area

0.778

135

0.631

84

0.505

49

 TAPSE

0.006

137

0.033

86

0.220

49

 LV-EI

0.613

111

0.896

72

0.282

38

 RV pump function

< 0.0001

109

< 0.0001

85

0.499

49

Time to clinical worsening

 6MWD

< 0.0001*

109

0.02

65

0.047*

44

 NT-proBNP

0.024

102

0.07

63

0.485

39

 WHO-FC

0.001

122

< 0.0001*

74

0.346

48

 RA area

0.002

133

0.067

82

0.074

51

 RV area

0.017

135

0.073

84

0.342

51

 TAPSE

0.049

137

0.071

86

0.679

51

 LV-EI

0.096

111

0.398

72

0.065

39

 RV pump function

< 0.0001*

135

< 0.0001

84

0.344

51

  1. 6MWD 6-min walking distance, NT-proBNP: n-terminal pro brain natriuretic peptide, WHO-FC World Health Organization Functional Class, RA right atrial, RV right ventricular, TAPSE tricuspid annular plane systolic excursion, LV-EI left ventricular eccentricity index. Parameters that were used for multivariate analysis are written in bold. *Denotes significant parameters in multivariate analysis